Evidence map›Paper›PMID 30232463›Full record

ArticleLeukemia2018

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

S Degryse, C E de Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke, K Jacobs, S Binos, D A Skerrett-Byrne, H C Murray and 4 more

Open access · bronzeAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 55 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

S DegryseVIB Center for Cancer Biology, Leuven, Belgium.
C E de BockVIB Center for Cancer Biology, Leuven, Belgium.
S DemeyerVIB Center for Cancer Biology, Leuven, Belgium.
I GovaertsVIB Center for Cancer Biology, Leuven, Belgium.
S BornscheinVIB Center for Cancer Biology, Leuven, Belgium.
D VerbekeVIB Center for Cancer Biology, Leuven, Belgium.
K JacobsVIB Center for Cancer Biology, Leuven, Belgium.
S BinosThermo Fisher Scientific, Scoresby, VIC, Australia.
D A Skerrett-ByrneFaculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia.
H C MurrayFaculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia.
N M VerrillsFaculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia.
P Van VlierbergheDepartment of Pediatrics and Genetics, Center for Medical Genetics, Ghent University, Ghent, Belgium.
J CoolsVIB Center for Cancer Biology, Leuven, Belgium. jan.cools@kuleuven.vib.be.
M D DunFaculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia. matt.dun@newcastle.edu.au.
KU Leuven · BEUniversity of Newcastle Australia · AUVIB-KU Leuven Center for Cancer Biology · BEGhent University Hospital · BEHunter Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of this article the authors noted that data describing precisely where phosphorylation sites in proteins modulated following JAK1 or JAK3 inhibition in mutant T-ALL samples was not clearly annotated. Therefore an additional sheet has been added to Supplementary Table 2.

Identifiers

PMID30232463
PMCPMC7609275
OpenAlexW2751598965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.